Rybelsus (oral semaglutide) Summary of Product Characteristics (EPAR product information)
Aetnas typical PA requirements for Wegovy and Zepbound include: Documented BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea) Evidence of participation in a structured weight management program (diet, exercise, behavioral counseling) for a minimum period often 3 to 6 months Documentation that other weight loss interventions have been attempted Prescriber must be a physician, NP, or PA with appropriate prescribing authority Prior authorization is not a denial it is a documentation requirement
Research into N-acetylcysteine (NAC) , a glutathione precursor, has shown some promising results in small trials
10.2147/OTT.S227915 68 HershmanJ
While the current body of evidence has predominantly focused on fat versus lean mass, relatively few studies (mostly subgroup analyses) have examined SMI, ASMI, and physical performance